Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus

British Journal of Clinical Pharmacology

Volumn 45, Issue 3, 1998, Pages 291-299

  Rabbone, I ^a   Piccinini, M ^a   Curto, M ^a   Mostert, M ^a   Gamba, S ^b   Mioletti, S ^a   Bruno, R ^a   Rinaudo, M T ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIA VITTORIA HOSPITAL   (Italy)

^c Sezione di Biochimica   (Italy)

Author keywords

Circulating lymphocytes; NIDDM; Pyruvate dehydrogenase; Sulphonylureas

Indexed keywords

GLICLAZIDE; INSULIN; PYRUVATE DEHYDROGENASE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LYMPHOCYTE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LYMPHOCYTES; MALE; MIDDLE AGED; PYRUVATE DEHYDROGENASE COMPLEX;

EID: 0031916853     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00680.x     Document Type: Article

References (44)

1. Prince MJ, Olefsky JM. Direct in vitro effect of a sulphonylurea to increase human fibroblast insulin receptors. J Clin Invest 1980; 66: 608-611.
2. DeFronzo RA, Simonson DC. Oral sulphonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984; 7 Suppl 1: 72-81.
3. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-1245.
4. Henquin JC. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?. Diabetologia 1992; 35: 907-912.
5. Müller G, Wied S. The sulphonylurea drug glimepiride stimulates glucose transport, glucose transporter translocation and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 1993; 42: 1852-1867.
6. Müller G, Dearey EA, Pünter J. The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes. Biochem J 1993; 289: 509-521.
7. Bahr M, Von-Holtey M, Müller G, Eckel J. Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulphonylurea glimepiride. Endocrinology 1995; 136: 2547-2553.
8. Rinaudo MT, Curto M, Rabbone I, et al. Effect of sulphonylurea agents on pyruvate dehydrogenase activity in circulating lymphocytes from patients with non-insulin-dependent diabetes mellitus (NIDDM). J Diab Comp 1994; 8: 221-225.
9. Mandarino LJ. Regulation of skeletal muscle pyruvate dehydrogenase and glycogen synthase in man. Diabetes-Metabolism Rev 1989; 5: 475-486.
10. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337-343.
11. Beck-Nielsen H, Vaag A, Damsbo P, et al. Insulin resistance in skeletal muscle in patients with NIDDM. Diabetes Care 1992; 15: 418-429.
12. Kelley DE, Mandarino LJ. Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in non-insulin-dependent diabetes mellitus. J Clin Invest 1990; 86: 1999-2007.
13. Kelley DE, Mokan M, Mandarino LJ. Intracellular defects in glucose metabolism in obese patients with NIDDM. Diabetes 1992; 41: 698-706.
14. Mandarino LJ, Madar Z, Kolterman OI, Bell JO, Olefsky JM. Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic subjects. Am J Physiol 1986; 251 (Endocrinol. Metab. 14), E489-496.
15. Wieland OH, Siess E, Schulze-Wethmar FH, Von Fimcke HG, Winton B. Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney. Effect of diabetes, fasting and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys 1971; 143: 593-601.
16. Wieland OH, Patzelt C, Löffler G. Active and inactive forms of pyruvate dehydrogenase in rat liver. Effect of starvation and refeeding and of insulin treatment on pyruvate dehydrogenase interconversion. Eur J Biochem 1972; 26: 426-433.
17. Stansbie D, Denton RM, Bridges BJ, Pask HT, Randle PJ. Regulation of pyruvate dehydrogenase and pyruvate dehydrogenase phosphate phosphatase activity in rat epididymal fat-pads. Biochem J 1976; 154: 225-236.
18. Hagg SA, Taylor SI, Ruderman NB. Glucose metabolism in perfused skeletal muscle. Pyruvate dehydrogenase activity in starvation, diabetes and exercise Biochem J 1976; 158: 203-210.
19. Rinaudo MT, Curto M, Bruno R. Effect of insulin on pyruvate dehydrogenase in a mixture of plasma membranes and mitochondria from normal and alloxan treated rat brains. Int J Biochem 1986; 18: 603-607.
20. Rinaudo MT, Curto M, Bruno R, Marino C, Mostert M. Effects of insulin on pyruvate dehydrogenase in circulating lymphocytes from normal and diabetic rats. Int J Biochem 1988; 20: 667-674.
21. Mondon CE, Jones IR, Azhar S, Hollenbech CB, Reave GM. Lactate production and pyruvate dehydrogenase activity in fat and skeletal muscle from diabetic rats. Diabetes 1992; 41: 1547-1554.
22. Rinaudo MT, Curto M, Bruno R, et al. The behaviour of pyruvate dehydrogenase in circulating lymphocytes from diabetic children. Diabetologia 1989; 32: 245-248.
23. Pellacani A, Curto M, Piccinini M, et al. Pyruvate dehydrogenase (PDH) as a marker of impaired glucose tolerance (IGT). Diabetologia 1995; 122: (suppl. 1), A 33.
24. Curto M, Piccinini M, Bruno I, Mostert M, Rinaudo MT. Insulin modulation of pyruvate dehydrogenase in human circulating lymphocytes. Int J Biochem 1988; 20: 1211-1217.
25. Curto M, Piccinini M, Marino C, Mostert M, Bruno R, Rinaudo MT. Pyruvate dehydrogenase activation by insulin in human circulating lymphocytes and the possible pathway involved. Int. J Biochem 1990; 22: 99-106.
26. Wieland OH. The mammalian pyravate dehydrogenase complex: Structure and regulation. Rev Physiol Biochem Pharmacol 1983; 96: 123-170.
27. 32Pi into pyruvate dehydrogenase phosphate in mitochondria from control and insulin-treated adipose tissue. Nature 1976; 264: 471-473.
28. Popp DA, Kiechle FL, Kotagal N, Jarett L. Insulin stimulation of pyruvate dehydrogenate in an isolated plasma membrane-mitochondrial mixture occurs by activation of pyruvate dehydrogenase phosphatase. J Biol Chem 1980; 255: 7540-7543.
29. Thomas AP, Diggle TA, Denton RM. Use of toluene-permeabilized mitochondria to study the regulation of adipose tissue pyruvate dehydrogenase in situ. Biochem J 1986; 238: 83-91.
30. Rutter GA, Diggle TA, Denton RM. Regulation of pyruvate dehydrogenase by insulin and polyamines within electropermeabilized fat-cells and isolated mitochondria. Biochem J 1992; 285: 435-439.
31. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1045.
32. Curto M, Piccinini M, Cerutti F, et al. The insulin signal and its effects on the pyruvate dehydrogenase complex in circulating lymphocytes of obese children. Int J Biochem 1992; 24: 831-837.
33. Teague WM, Pettit FH, Wu TL, Silberman SR, Reed LJ. Purification and properties of pyruvate dehydrogenase phophatase from bovine heart and kidney. Biochemistry 1982; 21: 5585-5592.
34. Reich JG, Wangermann G, Falk M, Rohde K. A general strategy for parameter estimation from isoteric and allosteric kinetic data and binding measurements. Eur J Biochem 1972; 26: 368-379.
35. Saltiel AR, Siegel MI, Jacobs S, Cuatrecasas P. Putative mediators of insulin action: Regulation of pyruvate dehydrogenase and adenylate cyclase activities. Proc Natl Acad Sci USA 1982; 79: 3513-3517.
36. Gottschalk WK, Jarett L. The insulinomimetic effects of the polar head group of an insulin-sensitive glycophospholipid on pyruvate dehydrogenase in both subcellular and whole cell assays. Arch Biochem Biophys 1988; 15: 175-185.
37. Jarett L, Seals JR. Pyruvate dehydrogenase activation in adipocyte mitochondria by an insulin generated mediator from muscle. Science 1979; 206: 1407-1408.
38. Cheng K, Galasko G, Huang L, Kellog J, Larner J. Studies of the insulin mediator - II Separation of two antagonistic biologically active materials from fraction II. Diabetes 1980; 29: 659-661.
39. Jarett L, Kiechle FL, Popp DA, Kotagal N, Gavin JR. Differences in the effects of insulin on the generation by adipocytes and IM-9 lymphocytes of a chemical mediator which stimulates the action of insulin on pyruvate dehydrogenase Biochem Biophys Res Commun 1980; 96: 735-741.
40. Saltiel AR. Second messengers of insulin action. Diabetes Care 1990; 13: 244-256.
41. Lilley K, Zhang C, Villar-Palasi C, Larner J, Huang L. Insulin mediator stimulation of pyruvate dehydrogenase phophatase. Arch Biochem Biophys 1992; 296: 170-174.
42. Campbell DB, Taylor A, Taylor D, et al. The biodisposition and pharmacodynamics of gliclazide in man. FADL Publishers, Servier Research & Development Ltd, Fulner Hall, Slough, Bucks, England 1987: 24-314.
43. Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 239-245.
44. Bak JF, Schmitz O, Sorensen NS, Pedersen O. Postreceptor effects of sulphonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes 1989; 38: 1343-1350.